You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 166 No. 17, September 25, 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Cardiovascular Interventions, Other
 •Nutrition/ Malnutrition
 •Cardiovascular System
 •Surgery
 •Cardiovascular/ Cardiothoracic Surgery
 •Transplantation
 •Cardiac Transplantation
 •Review
 •Congestive Heart Failure/ Cardiomyopathy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Amyloidosis and the Heart

A Comprehensive Review

Keyur B. Shah, MD; Yoshio Inoue, MD; Mandeep R. Mehra, MD

Arch Intern Med. 2006;166:1805-1813.

Infiltration of the heart from insoluble protein deposits in amyloidosis often results in restrictive cardiomyopathy that manifests late in its course with heart failure and conduction abnormalities. While the rare primary amyloidosis–related heart disease has been well characterized, senile amyloidosis occurring in the seventh decade of life most frequently affects the heart. Early diagnosis of cardiac amyloidosis may improve outcomes but requires heightened suspicion and a systematic clinical approach to evaluation. Demonstration of tissue infiltration of biopsy specimens using special stains, followed by immunohistochemical studies and genetic testing, is essential in defining the specific protein involved. The therapeutic strategy depends on the characterization of the type of amyloid protein and extent of disease and may include chemotherapy, stem cell transplantation, and liver transplantation. Heart transplantation is controversial and is generally performed only at isolated centers.


Author Affiliations: Division of Cardiology, University of Maryland School of Medicine, Baltimore.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition
Biolo et al.
Circ Heart Fail 2008;1:249-257.
ABSTRACT | FULL TEXT  

Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy.
Vogelsberg et al.
J Am Coll Cardiol 2008;51:1022-1030.
ABSTRACT | FULL TEXT  

Myocardial contrast echocardiography in biopsy-proven primary cardiac amyloidosis
Abdelmoneim et al.
Eur J Echocardiogr 2008;9:338-341.
ABSTRACT | FULL TEXT  

Giant Eustachian valve and left ventricular systolic dysfunction in a patient with non-dilated amyloid cardiomyopathy
Arora et al.
Eur J Echocardiogr 2008;9:145-147.
ABSTRACT | FULL TEXT  

Evaluation and Management of the Cardiac Amyloidosis
Selvanayagam et al.
J Am Coll Cardiol 2007;50:2101-2110.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.